For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients

The U.S. Food & Drug Administration (FDA) recently removed its Risk Evaluation and Mitigation Strategies (REMS) designation from CAR T immunotherapies. REMS is occasionally applied to drugs with serious potential safety issues, requiring providers to pursue and document more robust mitigation strategies. The FDA puts these designations in place to ensure patients receive the maximum…

Read More

Healthcare claim denial statistics: State of Claims Report 2025

Key takeaways: As claims denial rates continue to climb, pressure is mounting on healthcare organizations to find new ways to reduce denials. Leveraging artificial intelligence (AI) and automation-based tools, like Experian Health’s AI Advantage™ and Patient Access Curator™ solutions, is proven to lower denial rates. More than half of survey respondents say they’d replace existing…

Read More

Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable

Recently, the Trump administration announced expanded Medicare coverage of GLP-1s for beneficiaries with a body mass index (BMI) of 35 or greater, or a BMI of 27 or greater with certain chronic conditions including prediabetes, heart disease and failure, and kidney disease. This is a massive and needed expansion of coverage. Research has shown that…

Read More